Susquehanna International Group’s Amneal Pharmaceuticals AMRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $653K | Sell |
52,543
-1,273,997
| -96% | -$17.1M | ﹤0.01% | 8974 |
|
|
2025
Q4 | $16.7M | Buy |
1,326,540
+47,892
| +4% | +$548K | ﹤0.01% | 2400 |
|
|
2025
Q3 | $12.8M | Buy |
1,278,648
+155,305
| +14% | +$1.39M | ﹤0.01% | 2717 |
|
|
2025
Q2 | $9.09M | Buy |
1,123,343
+686,546
| +157% | +$5.18M | ﹤0.01% | 2966 |
|
|
2025
Q1 | $3.66M | Buy |
436,797
+274,488
| +169% | +$2.29M | ﹤0.01% | 4255 |
|
|
2024
Q4 | $1.29M | Buy |
162,309
+132,383
| +442% | +$1.11M | ﹤0.01% | 6348 |
|
|
2024
Q3 | $249K | Buy |
+29,926
| New | +$234K | ﹤0.01% | 10018 |
|
|
2024
Q2 | – | Sell |
-666,754
| Closed | -$4.23M | – | 11959 |
|
|
2024
Q1 | $4.04M | Sell |
666,754
-51,249
| -7% | -$289K | ﹤0.01% | 3994 |
|
|
2023
Q4 | $4.36M | Buy |
718,003
+72,147
| +11% | +$321K | ﹤0.01% | 3937 |
|
|
2023
Q3 | $2.73M | Buy |
645,856
+469,308
| +266% | +$1.75M | ﹤0.01% | 4553 |
|
|
2023
Q2 | $547K | Buy |
176,548
+124,893
| +242% | +$266K | ﹤0.01% | 8104 |
|
|
2023
Q1 | $71.8K | Buy |
51,655
+14,267
| +38% | +$28.4K | ﹤0.01% | 11516 |
|
|
2022
Q4 | $74.4K | Sell |
37,388
-26,899
| -42% | -$60.3K | ﹤0.01% | 11189 |
|
|
2022
Q3 | $130K | Sell |
64,287
-729
| -1% | -$2.04K | ﹤0.01% | 11421 |
|
|
2022
Q2 | $207K | Sell |
65,016
-197,127
| -75% | -$714K | ﹤0.01% | 10543 |
|
|
2022
Q1 | $1.09M | Buy |
262,143
+247,856
| +1,735% | +$1.1M | ﹤0.01% | 6878 |
|
|
2021
Q4 | $68K | Sell |
14,287
-604
| -4% | -$3.01K | ﹤0.01% | 12396 |
|
|
2021
Q3 | $80K | Sell |
14,891
-15,955
| -52% | -$80.3K | ﹤0.01% | 12173 |
|
|
2021
Q2 | $158K | Buy |
+30,846
| New | +$175K | ﹤0.01% | 11812 |
|
|
2021
Q1 | – | Sell |
-51,764
| Closed | -$287K | – | 12191 |
|
|
2020
Q4 | $237K | Buy |
51,764
+39,784
| +332% | +$176K | ﹤0.01% | 9749 |
|
|
2020
Q3 | $46K | Sell |
11,980
-13,674
| -53% | -$58.5K | ﹤0.01% | 10218 |
|
|
2020
Q2 | $122K | Sell |
25,654
-194,074
| -88% | -$799K | ﹤0.01% | 9395 |
|
|
2020
Q1 | $765K | Sell |
219,728
-89,254
| -29% | -$378K | ﹤0.01% | 5982 |
|
|
2019
Q4 | $1.49M | Sell |
308,982
-46,699
| -13% | -$162K | ﹤0.01% | 4813 |
|
|
2019
Q3 | $1.03M | Buy |
355,681
+276,897
| +351% | +$966K | ﹤0.01% | 5622 |
|
|
2019
Q2 | $565K | Buy |
+78,784
| New | +$806K | ﹤0.01% | 7032 |
|
|
2019
Q1 | – | Sell |
-12,621
| Closed | -$167K | – | 8747 |
|
|
2018
Q4 | $171K | Buy |
12,621
+3,105
| +33% | +$56K | ﹤0.01% | 7878 |
|
|
2018
Q3 | $211K | Sell |
9,516
-155,260
| -94% | -$3.27M | ﹤0.01% | 8116 |
|
|
2018
Q2 | $2.7M | Buy |
+164,776
| New | +$2.89M | ﹤0.01% | 3531 |
|
Other funds holding AMRX
TGA
VPM
RCMNY
VCM
Susquehanna International Group's AMRX Position: Q1 2026 in Review
Susquehanna International Group reduced its Amneal Pharmaceuticals (AMRX) stake by 96% in Q1 2026, selling an estimated $17.1M and leaving 52,543 shares worth $653K. The position accounts for ﹤0.01% of the portfolio, ranked #8974.
Susquehanna International Group first reported a position in AMRX in Q2 2018 and has held it in 29 quarters since. The position peaked at $16.7M in Q4 2025. 316 funds tracked by Wall St. Rank hold AMRX as of Q1 2026.
- Susquehanna International Group held 52,543 shares of Amneal Pharmaceuticals worth $653K as of Q1 2026.
- Susquehanna International Group sold 1,273,997 Amneal Pharmaceuticals shares in Q1 2026, an estimated $17.1M.
- Amneal Pharmaceuticals made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #8974 holding.
- Susquehanna International Group first reported a position in Amneal Pharmaceuticals in Q2 2018 and has held it in 29 quarters since.
- Susquehanna International Group's Amneal Pharmaceuticals position peaked at $16.7M in Q4 2025.
- 316 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q1 2026.
Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.